Use of a Modeling Framework to Evaluate the Effect of a Modifier Gene (MBL2) on Variation in Cystic Fibrosis

Overview

Journal Eur J Hum Genet

Specialty Genetics

Date 2010 Jan 14

PMID 20068595

Citations 11

Authors

Kathryn E McDougal

Deanna M Green

Lori L Vanscoy

M Daniele Fallin

Michael Grow

Suzanne Cheng

Scott M Blackman

J Michael Collaco

Lindsay B Henderson

Kathleen Naughton

Garry R Cutting

Affiliations

Soon will be listed here.

Abstract

Variants in mannose-binding lectin (MBL2; protein MBL) have shown association with different aspects (eg, lung function, infection, survival) of cystic fibrosis (CF) in some studies but not others. Inconsistent results may be due to confounding among disease variables that were not fully accounted for in each study. To account for these relationships, we derived a modeling framework incorporating CFTR genotype, age, Pseudomonas aeruginosa (Pa) infection, and lung function from 788 patients in the US CF Twin and Sibling Study. This framework was then used to identify confounding variables when testing the effect of MBL2 variation on specific CF traits. MBL2 genotypes corresponding to low levels of MBL associated with Pa infection 1.94 years earlier than did MBL2 genotypes corresponding to high levels of MBL (P=0.0034). In addition, Pa-infected patients with MBL2 genotypes corresponding to low levels of MBL underwent conversion to mucoid Pa 2.72 years earlier than did patients with genotypes corresponding to high levels of MBL (P=0.0003). MBL2 was not associated with the time to transition from infection to conversion or with lung function. Thus, use of a modeling framework that identified confounding among disease variables revealed that variation in MBL2 associates with age at infection with Pa and age at conversion to mucoid Pa in CF.

Citing Articles

Subversion of the Complement System by Pseudomonas aeruginosa.

Hastings C, Syed S, Marques C J Bacteriol. 2023; 205(8):e0001823.

PMID: 37436150 PMC: 10464199. DOI: 10.1128/jb.00018-23.

Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes.

Mesinele J, Ruffin M, Guillot L, Corvol H Int J Mol Sci. 2022; 23(22).

PMID: 36430680 PMC: 9698440. DOI: 10.3390/ijms232214205.

Applying whole-genome sequencing in relation to phenotype and outcomes in siblings with cystic fibrosis.

Wilk M, Braun A, Farrell P, Laxova A, Brown D, Holt J Cold Spring Harb Mol Case Stud. 2020; 6(1).

PMID: 32014855 PMC: 6996517. DOI: 10.1101/mcs.a004531.

Disease-modifying genes and monogenic disorders: experience in cystic fibrosis.

Gallati S Appl Clin Genet. 2014; 7:133-46.

PMID: 25053892 PMC: 4104546. DOI: 10.2147/TACG.S18675.

Genetic influences on cystic fibrosis lung disease severity.

Weiler C, Drumm M Front Pharmacol. 2013; 4:40.

PMID: 23630497 PMC: 3632778. DOI: 10.3389/fphar.2013.00040.

References

Trevisiol C, Boniotto M, Giglio L, Poli F, Morgutti M, Crovella S . MBL2 polymorphisms screening in a regional Italian CF Center. J Cyst Fibros. 2005; 4(3):189-91. DOI: 10.1016/j.jcf.2005.04.001. View

Sumiya M, Super M, Tabona P, Levinsky R, Arai T, Turner M . Molecular basis of opsonic defect in immunodeficient children. Lancet. 1991; 337(8757):1569-70. DOI: 10.1016/0140-6736(91)93263-9. View

Madsen H, Garred P, Kurtzhals J, Lamm L, Ryder L, Thiel S . A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics. 1994; 40(1):37-44. DOI: 10.1007/BF00163962. View

Renders N, Sijmons M, van Belkum A, Overbeek S, Mouton J, Verbrugh H . Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings. Res Microbiol. 1997; 148(5):447-54. DOI: 10.1016/s0923-2508(97)83875-2. View

Vanscoy L, Blackman S, Collaco J, Bowers A, Lai T, Naughton K . Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med. 2007; 175(10):1036-43. PMC: 1899267. DOI: 10.1164/rccm.200608-1164OC. View

Cutting G . Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet. 2005; 6:237-60. DOI: 10.1146/annurev.genom.6.080604.162254. View

Kosorok M, Zeng L, West S, Rock M, Splaingard M, Laxova A . Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001; 32(4):277-87. DOI: 10.1002/ppul.2009.abs. View

Madsen H, Garred P, Thiel S, Kurtzhals J, Lamm L, Ryder L . Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol. 1995; 155(6):3013-20. View

Baxter N, Sumiya M, Cheng S, Erlich H, Regan L, Simons A . Recurrent miscarriage and variant alleles of mannose binding lectin, tumour necrosis factor and lymphotoxin alpha genes. Clin Exp Immunol. 2001; 126(3):529-34. PMC: 1906238. DOI: 10.1046/j.1365-2249.2001.01663.x. View

10.

Bremer L, Blackman S, Vanscoy L, McDougal K, Bowers A, Naughton K . Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet. 2008; 17(14):2228-37. PMC: 2902288. DOI: 10.1093/hmg/ddn123. View

11.

Horiuchi T, Gondo H, Miyagawa H, Otsuka J, Inaba S, Nagafuji K . Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun. 2005; 6(2):162-6. DOI: 10.1038/sj.gene.6364165. View

12.

Dorfman R, Sandford A, Taylor C, Huang B, Frangolias D, Wang Y . Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008; 118(3):1040-9. PMC: 2248329. DOI: 10.1172/JCI33754. View

13.

Wang X, Myers A, Saiki R, Cutting G . Development and evaluation of a PCR-based, line probe assay for the detection of 58 alleles in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Clin Chem. 2002; 48(7):1121-3. View

14.

Nixon G, Armstrong D, Carzino R, Carlin J, Olinsky A, Robertson C . Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001; 138(5):699-704. DOI: 10.1067/mpd.2001.112897. View

15.

Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson R, Goss C . Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2005; 172(7):885-91. DOI: 10.1164/rccm.200410-1335OC. View

16.

Ballmann M, Rabsch P, von der Hardt H . Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax. 1999; 53(9):732-7. PMC: 1745320. DOI: 10.1136/thx.53.9.732. View

17.

Collaco J, Vanscoy L, Bremer L, Mcdougal K, Blackman S, Bowers A . Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA. 2008; 299(4):417-24. PMC: 3139475. DOI: 10.1001/jama.299.4.417. View

18.

Gabolde M, Guilloud-Bataille M, Feingold J, Besmond C . Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. BMJ. 1999; 319(7218):1166-7. PMC: 28266. DOI: 10.1136/bmj.319.7218.1166. View

19.

Garred P, Pressler T, Madsen H, Frederiksen B, Svejgaard A, Hoiby N . Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest. 1999; 104(4):431-7. PMC: 408526. DOI: 10.1172/JCI6861. View

20.

Ohlenschlaeger T, Garred P, Madsen H, Jacobsen S . Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med. 2004; 351(3):260-7. DOI: 10.1056/NEJMoa033122. View